Review of Treatments and Guidelines in the Management of Type 2 Diabetes Mellitus

Didin't officially launch until November 20, 2019

Faculty

Needs Statement

There have been frequent updates to the diabetes management guidelines and recent data that led to updates to the treatment algorithm for the management of type 2 diabetes mellitus (T2DM) that pharmacists need to be aware of.

Target Audience

Pharmacist

Objectives

Upon completion of this activity, participants will be able to:
1. Review drug classes endorsed by the current treatment guidelines for T2DM.
2. Discuss the FDA Guidance for Industry that led to recent updates to the T2DM Guidelines.
2. Discuss literature that led to updates to the T2DM pharmacological treatment algorithm.

Accreditation

CPE
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-0000-18-172-H01-P and will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Faculty Disclosure

No speakers or planners have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

CE Content Concerns

Policy

Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504

Procedures

• The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
• If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
• Issues regarding activity content also will be reviewed and addressed by the Activity Director.
• A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
• Grievances will be considered when planning future activities.

Appeal Procedure

• Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
• The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
• The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.